U.S. sets $1.74 billion deal with Moderna for updated Covid-19 vaccine
July 29 (Reuters) - The U.S. government said on Friday it agreed to a $1.74 billion deal for 66 million doses of a Moderna Inc MRNA.O Covid-19 vaccine updated for the Omicron subvariant for use in a fall and winter booster campaign, sending Moderna shares up 3%.
Combined with 105 million doses the government already agreed to buy from Pfizer Inc PFE.N and partner BioNTech SE 22UAy.DE for $3.2 billion, the latest deal puts the U.S. booster dose supply at about 171 million shots.
COVID-19 infections in the United States have been on the rise as the BA.4 and BA.5 subvariants of the Omicron variant have spread to account for more than 90% of U.S. infections, according the U.S. Centers for Disease Control and Prevention.
These subvariants have significant mutations from the earliest versions of Omicron and protection from vaccines wanes over time.
The U.S. Food and Drug Administration in June recommended that vaccine manufacturers target these subvariants for a potential fall season booster dose in a bivalent vaccine that also includes the original strain.
Moderna’s initial 66 million doses are for delivery this year. The government’s deals with Moderna and Pfizer could go up to 300 million doses from each company if it exercises all of its options and secures funding from the Congress.
“As we look to the fall and winter… we are ensuring Americans have the tools they need to stay safe and help keep our nation moving forward,” U.S. Department of Health and Human Services Secretary Xavier Becerra said in a statement.
The booster candidates need to secure FDA authorization and a recommendation by the U.S. Centers for Disease Control and Prevention, before they can be made available for wider use.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Caroline Humer and Shailesh Kuber)
"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"